Semaglutide, a medication primarily prescribed for obesity and type 2 diabetes, significantly reduces cardiac filling pressures during physical exertion in patients suffering from heart failure with preserved ejection fraction and obesity, according to a clinical trial published in Nature Medicine.
The study, titled CAMEO-SEMA, evaluated 81 participants—including 47 women—who were randomly assigned to receive either 2.4 milligrams of semaglutide weekly or a placebo for 52 weeks. Researchers used a catheter to directly measure pulmonary capillary wedge pressure, a key metric for estimating the filling pressures of the heart’s left side, during light physical activity.
At the study’s outset, the mean pressure rose sharply from 17.5 mmHg at rest to 31.7 mmHg during physical activity. After one year of treatment, exercising filling pressures in the semaglutide cohort dropped by a mean of 9.8 mmHg, compared to a meager 0.9 mmHg increase in the placebo group. The estimated difference between the two groups reached 10.6 mmHg favoring the drug, alongside a 7.1 mmHg reduction at rest.
A secondary analysis utilizing cardiac magnetic resonance imaging on 49 CAMEO-SEMA participants revealed improvements in left atrial function and left ventricular filling. These physiological changes tracked closely with the observed drops in exercise-induced cardiac stress. Prior investigations, including the STEP-HFpEF trials, established that the therapy alleviated physical limitations and reduced symptoms. This new trial moves past subjective reporting to quantify how the heart handles physical workloads.
- Preserved Ejection Fraction: This means the heart squeezes out a normal percentage of blood, but the muscle remains stiff and struggles to fill up properly without dangerously high internal pressure.
- Pulmonary Wedge Pressure: Doctors thread a tiny tube into the blood vessels of the lungs to measure how much backpressure the failing left side of the heart is creating.
- Hemodynamic Remission: A specific research milestone where measured pressures fall back below pre-set clinical thresholds, though it does not mean the underlying heart disease has vanished.
Investigators noted a striking metric they termed “hemodynamic remission,” defined as pressures returning below predefined thresholds both at rest and during exercise. This threshold was met by 53.7% of participants treated with semaglutide, compared to just 7.4% in the placebo group. The term remission must be handled carefully because it does not equate to a full clinical remission of heart failure.
Excess adipose tissue—fat tissue—in obesity alters blood volume, systemic inflammation, and baseline myocardial function.
| Clinical Parameter | Semaglutide Group (2.4 mg) | Placebo Group |
|---|---|---|
| Sample Size (N) | 47 women, 81 participants total | 47 women, 81 participants total |
| Change in Exercise Pressure | -9.8 mmHg reduction | +0.9 mmHg increase |
| Hemodynamic Remission Rate | 53.7% | 7.4% |
| Trial Duration | 52 weeks | 52 weeks |
Clinical enthusiasm must be tempered by the study’s precise boundaries. With 81 participants observed over a single year, the trial was explicitly powered to assess hemodynamic parameters rather than hard clinical endpoints like hospitalizations or mortality rates. The findings apply strictly to patients presenting with the dual profile of obesity and heart failure with preserved ejection fraction.
- Borlaug, B.A., Jensen, M.D., Packer, M. et al. Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial. Nature Medicine, Nov 8, 2026. DOI: 10.1038/s41591-026-04762-3.
